Maccura reports third quarter 2025 impairment provisions amid revenue and profit drops

Maccura Biotechnology will provide for credit and asset impairment losses totaling CNY 20,649,500 for the third quarter of 2025, impacting its profit by an equivalent amount and reducing net profit attributable to shareholders by CNY 17,634,000. This includes credit impairment losses of CNY 15,184,100, mainly from accounts receivable, and asset impairment losses of CNY 5,465,500, primarily from inventory write-downs.

The company’s third-quarter report for 2025 highlights a 20.32% year-on-year decrease in operating revenue to CNY 532,849,978.83 and a 96.16% drop in net profit attributable to shareholders to CNY 3,060,863.16. For the first nine months of 2025, operating revenue decreased by 17.44% to CNY 1,607,884,075.22, and net profit attributable to shareholders decreased by 86.81% to CNY 37,103,351.99.

Significant corporate actions for the period include a reduction in registered capital through the cancellation of 7,802,966 shares, changing the total share capital to 604,666,624 shares. The company also transferred its 51% equity interest in Shandong Maccura Biotechnology Co., Ltd. for CNY 17,412,879.00.